VistaGen Therapeutics Inc Asset Resilience Ratio
VistaGen Therapeutics Inc asset resilience ratio. VistaGen Therapeutics Inc (VTGN) has an Asset Resilience Ratio of 30.09% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can VistaGen Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of VistaGen Therapeutics Inc (2017–2026)
Asset resilience ratio of VistaGen Therapeutics Inc from 2017 to 2026. This chart shows how VistaGen Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of VistaGen Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down VistaGen Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VistaGen Therapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.61 Million | 30.09% |
| Total Liquid Assets | $14.61 Million | 30.09% |
Asset Resilience Insights
- Very High Liquidity: VistaGen Therapeutics Inc maintains exceptional liquid asset reserves at 30.09% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
VistaGen Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare VistaGen Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
VistaGen Therapeutics Inc Asset Resilience Ratio by Year (2017–2026)
VistaGen Therapeutics Inc asset resilience ratio by year from 2017 to 2026. The table below shows the annual Asset Resilience Ratio data for VistaGen Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 30.09% | $14.61 Million | $48.56 Million | +14.26pp |
| 2025-03-31 | 15.83% | $13.35 Million | $84.34 Million | -- |
| 2024-03-31 | 0.00% | $0.00 | $123.65 Million | -- |
| 2018-03-31 | 0.00% | $0.00 | $11.28 Million | -- |
| 2017-03-31 | 0.00% | $0.00 | $3.71 Million | -- |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more